NCT02588092: Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) |
|
|
| Terminated | 1 | 35 | US | ADCT-301, Camidanlumab tesirine | ADC Therapeutics S.A. | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | 08/18 | 08/18 | | |
| Completed | 1 | 133 | Europe, US | Camidanlumab tesirine, ADCT-301, Cami | ADC Therapeutics S.A. | Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 10/19 | 10/19 | | |
NCT03621982: Study of ADCT-301 in Patients With Selected Advanced Solid Tumors |
|
|
| Terminated | 1 | 78 | Europe, US | ADCT-301, Camidanlumab tesirine, Pembrolizumab, Keytruda | ADC Therapeutics S.A. | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer | 12/22 | 12/22 | | |
